Chiesi Group has entered an exclusive licensing agreement with Aliada Therapeutics, a subsidiary of AbbVie, to develop therapies that can cross the blood-brain barrier (BBB) for lysosomal storage disorders (LSDs). These conditions often involve severe neurological complications that remain largely untreated.

The collaboration focuses on leveraging Aliada’s proprietary BBB-crossing platform to deliver enzyme replacement therapies directly to the brain. This approach aims to address the underlying neurological burden rather than just managing symptoms. Chiesi will fund global research, development, and commercialization, while Aliada will receive upfront payments, milestone-based incentives, and royalties.

This agreement builds on a research partnership initiated in 2023, which explored the MODEL platform, a technology designed to transport large molecules across the BBB using natural cellular mechanisms. Early preclinical data have shown promise in improving therapeutic delivery to the central nervous system.

Chiesi Group, a certified B Corp and Benefit Corporation, emphasizes sustainability and equitable access to care. With operations in over 30 countries and a strong rare disease division, the company continues to pursue innovative solutions for underserved patient populations.